articleNature MedicineAug 1, 2022HYBRID OA

Circulating tumor DNA to guide rechallenge with panitumumab in metastatic colorectal cancer: the phase 2 CHRONOS trial

ASAndrea Sartore‐BianchiFPFilippo PietrantonioSLSara LonardiBMBenedetta MussolinFRFrancesco Rua

University of Milan · Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda · +8 more institutions

PubMed
Indexed incrossrefpubmed

Abstract

Anti-epidermal growth factor receptor (EGFR) monoclonal antibodies are approved for the treatment of RAS wild-type (WT) metastatic colorectal cancer (mCRC), but the emergence of resistance mutations restricts their efficacy. We previously showed that RAS, BRAF and EGFR mutant alleles, which appear in circulating tumor DNA (ctDNA) during EGFR blockade, decline upon therapy withdrawal. We hypothesized that monitoring resistance mutations in blood could rationally guide subsequent therapy with anti-EGFR antibodies. We report here the results of CHRONOS, an open-label, single-arm phase 2 clinical trial exploiting blood-based identification of RAS/BRAF/EGFR mutations levels to tailor a chemotherapy-free anti-EGFR…

Citation impact

253
total citations
FWCI
22.24
Percentile
100%
References
51
Citations per year

Authors

25

Topics & keywords

Topics
Keywords
  • Panitumumab
  • Medicine
  • Internal medicine
  • Oncology
  • Clinical endpoint
  • Colorectal cancer
  • Tolerability
  • Cetuximab
UN Sustainable Development Goals
  • Good health and well-being
No related works found for this paper.

Funding